Artículos por temáticas

Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification.

Bjørklund G, Hofer T, Nurchi VM, Aaseth J.

J Inorg Biochem. 2019 Oct;199:110717. doi: 10.1016/j.jinorgbio.2019.110717. Epub 2019 May 19.

5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.

Badillo-Ramírez I, Saniger JM, Rivas-Arancibia S.

Neurochem Int. 2019 Oct;129:104514. doi: 10.1016/j.neuint.2019.104514. Epub 2019 Jul 29. Review.

Orexins alleviate motor deficits via increasing firing activity of pallidal neurons in a mouse model of Parkinson's disease.

Wang Y, Chen AQ, Xue Y, Liu MF, Liu C, Liu YH, Pan YP, Diao HL, Chen L.

Am J Physiol Cell Physiol. 2019 Oct 1;317(4):C800-C812. doi: 10.1152/ajpcell.00125.2019. Epub 2019 Jul 31.

Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread.

Freeze B, Pandya S, Zeighami Y, Raj A.

Brain. 2019 Oct 1;142(10):3072-3085. doi: 10.1093/brain/awz223.

Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-κB signaling pathways.

Li Y, Zeng Y, Meng T, Gao X, Huang B, He D, Ran X, Du J, Zhang Y, Fu S, Hu G.

Int Immunopharmacol. 2019 Oct;75:105739. doi: 10.1016/j.intimp.2019.105739. Epub 2019 Jul 24.

IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.

Liu Z, Qiu AW, Huang Y, Yang Y, Chen JN, Gu TT, Cao BB, Qiu YH, Peng YP.

Brain Behav Immun. 2019 Oct;81:630-645. doi: 10.1016/j.bbi.2019.07.026. Epub 2019 Jul 24.

Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.

Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, Pieri L, Kiechle M, McLean PJ, Kassubek J, Behrends C, Ludolph AC, Weishaupt JH, Melki R, Danzer KM.

Ann Neurol. 2019 Oct;86(4):593-606. doi: 10.1002/ana.25557. Epub 2019 Aug 15.

Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Ceccarini J, Casteels C, Ahmad R, Crabbé M, Van de Vliet L, Vanhaute H, Vandenbulcke M, Vandenberghe W, Van Laere K.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2348-2357. doi: 10.1007/s00259-019-04445-x. Epub 2019 Jul 24.

The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson's disease: preliminary observations.

Veselý B, Koriťáková E, Bohnen NI, Viszlayová D, Királová S, Valkovič P, Kurča E, Rektor I.

J Neural Transm (Vienna). 2019 Oct;126(10):1303-1312. doi: 10.1007/s00702-019-02043-7. Epub 2019 Jul 22.

Standardized measurement of circulating vitamin D [25(OH)D] and its putative role as a serum biomarker in Alzheimer's disease and Parkinson's disease.

Bivona G, Lo Sasso B, Iacolino G, Gambino CM, Scazzone C, Agnello L, Ciaccio M.

Clin Chim Acta. 2019 Oct;497:82-87. doi: 10.1016/j.cca.2019.07.022. Epub 2019 Jul 19. Review.

Mental representation of the body in action in Parkinson's disease.

Scarpina F, Magnani FG, Tagini S, Priano L, Mauro A, Sedda A.

Exp Brain Res. 2019 Oct;237(10):2505-2521. doi: 10.1007/s00221-019-05608-w. Epub 2019 Jul 20.

Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models.

Wang L, Zhang Z, Hou L, Wang Y, Zuo J, Xue M, Li X, Liu Y, Song J, Pan F, Pu T.

Neurochem Int. 2019 Oct;129:104507. doi: 10.1016/j.neuint.2019.104507. Epub 2019 Jul 17.

A Gutsy Move for Cell-Based Regenerative Medicine in Parkinson's Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity.

Lee JY, Tuazon JP, Corey S, Bonsack B, Acosta S, Ehrhart J, Sanberg PR, Borlongan CV.

Stem Cell Rev Rep. 2019 Oct;15(5):690-702. doi: 10.1007/s12015-019-09906-2.

NEAT1 is overexpressed in Parkinson's disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress.

Simchovitz A, Hanan M, Niederhoffer N, Madrer N, Yayon N, Bennett ER, Greenberg DS, Kadener S, Soreq H.

FASEB J. 2019 Oct;33(10):11223-11234. doi: 10.1096/fj.201900830R. Epub 2019 Jul 17.

Downregulation of lncRNA UCA1 ameliorates the damage of dopaminergic neurons, reduces oxidative stress and inflammation in Parkinson's disease through the inhibition of the PI3K/Akt signaling pathway.

Cai L, Tu L, Li T, Yang X, Ren Y, Gu R, Zhang Q, Yao H, Qu X, Wang Q, Tian J.

Int Immunopharmacol. 2019 Oct;75:105734. doi: 10.1016/j.intimp.2019.105734. Epub 2019 Jul 10.